Trial · NCT03033511
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With Extensive-Stage Small Cell Lung Cancer With Delta-Like Protein 3 High Expression in Tumor (DLL3high) | Placebo | 9.79 | 95% Confidence Interval 8.38 to 10.87 | months | |
| Overall Survival (OS) in Participants With Extensive-Stage Small Cell Lung Cancer With Delta-Like Protein 3 High Expression in Tumor (DLL3high) | Rovalpituzumab Tesirine/Dexamethasone | 8.48 | 95% Confidence Interval 7.26 to 10.18 | months | |
| OS in All Randomized Participants | Placebo | 9.89 | 95% Confidence Interval 8.61 to 11.01 | months | |
| OS in All Randomized Participants | Rovalpituzumab Tesirine/Dexamethasone | 8.80 | 95% Confidence Interval 7.95 to 9.53 | months | |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 6 | -3.97 | Standard Error 1.00 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 6 | -4.34 | Standard Error 0.95 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 12 | -1.70 | Standard Error 1.67 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 12 | -12.13 | Standard Error 1.27 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 18 | 8.15 | Standard Error 4.02 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 18 | -19.52 | Standard Error 4.92 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 24 | -0.95 | Standard Error 7.32 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 24 | -19.39 | Standard Error 6.61 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 30 | 5.33 | Standard Error 4.22 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 30 | -16.67 | Standard Error 6.78 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 36 | -13.33 | Standard Error NA | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 36 | -13.33 | Standard Error NA | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 42 | -6.67 | Standard Error NA | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 42 | -3.33 | Standard Error NA | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Placebo | Change at Week 48 | -6.67 | Standard Error NA | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time | Rovalpituzumab Tesirine/Dexamethasone | Change at Week 48 | -63.33 | Standard Error NA | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03033511/results